Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EaAstGibb

ABSTRACT: Asterina gibbosa (Pennant, 1777) (cushion star)

PROVIDER: PRJEB78961 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR13510346.fastq.gz	Fastqsanger.gz
	ERR13510347.fastq.gz	Fastqsanger.gz
	ERR13621450_1.fastq.gz	Fastqsanger.gz
	ERR13621450_2.fastq.gz	Fastqsanger.gz
	ERR13621451_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

eaAstGibb

Project description:Asterina gibbosa (Pennant, 1777) (cushion star), genomic and transcriptomic data

| PRJEB78960 | ENA

eaAstPhyl

Project description:Asterina phylactica (the recursive cushion star)

| PRJEB78324 | ENA

eaAstPhyl4

Project description:Asterina phylactica (the recursive cushion star) genome assembly, eaAstPhyl4

| PRJEB78695 | ENA

eaAstPhyl

Project description:Asterina phylactica (the recursive cushion star), genomic and transcriptomic data

| PRJEB78323 | ENA

eaAstPhyl4 alternate haplotype

Project description:Asterina phylactica (the recursive cushion star) genome assembly, eaAstPhyl4, alternate haplotype

| PRJEB78696 | ENA

ATI-1777 a topical JAK1/3 inhibitor may benefit atopic dermatitis without systemic drug exposure, results from preclinical development and Phase 2a randomized-control study ATI-1777-AD-201

Project description:Atopic dermatitis (AD), a chronic, pruritic skin disease, affects 10%-30% of children and up to 14% of adults in developed countries. Since current AD treatments may lead to systemic drug exposure and AD pathophysiology is partially mediated by JAK1/3 signaling, ATI-1777, a potent and selective JAK1/3 inhibitor, was designed with multiple sites of metabolism to deliver local efficacy in the skin and limit systemic exposure. In preclinical studies, ATI-1777 selectively inhibited JAK1/3 with limited systemic exposure and without any adverse effects. ATI-1777-AD-201 (NCT04598269), a Phase 2a, first-in-human, randomized, double-blind,vehicle-controlled, parallel-group study, evaluated the efficacy, safety, tolerability, and pharmacokinetics of ATI-1777 topical solution in 48participants with AD over 4 weeks. The primary outcome was reduction of a modified EASI score from baseline; reduction was significantly greater in the ATI-1777 group at Day28 compared to vehicle (percent reduction from baseline 74.45% [SE6.455] and 41.43% [SE6.189], respectively [p<0.001]). Average plasma concentrations of ATI-1777 were <5% of the IC50 of ATI-1777 for inhibiting JAK1/3. No deaths or serious adverse events were reported. This demonstrates that topical ATI-1777 does not lead to pharmacologically relevant systemic drug exposure and may reduce clinical signs of AD.

2023-11-20 | GSE244201 | GEO

Asterina phylactica

Project description:Asterina phylactica overview

| PRJNA1145075 | ENA

Project description:alpine cushion plants

| PRJEB23958 | ENA

Ancula gibbosa

Project description:Ancula gibbosa

| PRJNA970769 | ENA

iuPsoGibb

Project description:Psococerastis gibbosa

| PRJEB71621 | ENA